What peptides do biohackers use most?

The peptides that come up most often in biohacking circles are BPC-157 and TB-500 for recovery, GHK-Cu for skin, and MOTS-c for metabolism, with the coenzyme NAD frequently grouped alongside them. Most of their evidence is preclinical, none is an approved human medicine, and all are sold for laboratory research use only.

Are biohacker peptides safe?

Their safety is genuinely uncertain. Because compounds like BPC-157, TB-500 and MOTS-c have barely been studied in people, their long-term human side-effect profiles are not well characterised, so a lack of reported harm reflects missing data rather than proven safety. Gray-market supply adds contamination and mislabelling risk on top.

Do biohacker peptides actually work?

For most, the honest answer is not proven. BPC-157, TB-500 and MOTS-c rest largely on animal studies; GHK-Cu's human data is mostly cosmetic; and a 2024 meta-analysis found the NAD precursor NMN gave no significant benefit for glucose or lipid measures. Being studied for a pathway is not the same as working in people.

Are biohacker peptides legal and regulated?

The research-grade peptides discussed here are sold for laboratory research use only, not for human consumption, and they are not FDA-approved for any human use. Several are also banned in competitive sport under anti-doping rules. Legality varies by country, but 'sold for research' is not the same as 'proven safe for people.'

Longevity

What Peptides Do Biohackers Actually Use? A Research Overview

By MrPepTalks Editorial · Updated 2026-07-16

If you have ever wondered what peptides biohackers actually use, the same short list keeps surfacing in forums, podcasts and self-optimisation subreddits: BPC-157, TB-500, GHK-Cu, NAD and MOTS-c. Each one gets framed as a tool for faster recovery, sharper metabolism, better skin or a slower biological clock. This overview takes the calmer route. Rather than hype a stack, it walks through the compounds that come up most often in biohacking circles and lines each one against the evidence that genuinely exists: where real studies were run, how strong they are, and where the human data simply stops. The honest headline, stated up front, is that most of the eye-catching results come from cell and animal research, and every compound here is sold strictly for laboratory research use, not for human consumption.

What people mean by a 'biohacker peptide'

'Biohacker peptide' is a community label, not a medical category. In practice it points to a handful of short amino-acid chains that laboratory research has linked to processes the self-optimisation world cares about: tissue repair, collagen production, cellular energy and the biology of aging. Modern aging science is organised around a set of shared cellular processes, often called the hallmarks of aging, that include mitochondrial decline, genomic instability and shifting communication between cells over time. When a peptide is described as one biohackers use, it is usually because a study tied it to one of these pathways in cells or animals. That overlap is why it enters the conversation; it is not, on its own, evidence that it does anything measurable in a healthy person.

How strong is the evidence, really?

Before the list, one framing tool worth carrying through it. Across this site we label each compound by the strength of its evidence: human randomised controlled trials sit at the top, small or early human studies in the middle, and cell, animal or mechanism-only work at the bottom — interesting biology, but a long way from a proven human benefit. The uncomfortable pattern for the biohacker shortlist is that almost every entry sits near the bottom of that scale. Keeping the label visible is the whole point of an honest roundup: it lets you see at a glance how thin or thick the human data really is before anyone sells you a protocol.

BPC-157: the most hyped, and almost entirely animal evidence

BPC-157 is a stable pentadecapeptide originally derived from a protein found in gastric juice, and it is the headline act of the biohacking recovery world. In controlled animal experiments it has been associated with improved healing of tendon, ligament and muscle injuries; one rat study of medial-collateral-ligament injury, for example, reported better functional and structural recovery in animals given the peptide than in untreated controls. Reviews of the field are blunt about the limits: the published work is dominated by small-animal models, and there are no completed clinical studies describing its efficacy in humans. So BPC-157 is best read as a genuinely interesting laboratory signal with an unusually thin human record. For the full study-by-study picture and how it earns its verdict, see our BPC-157 research breakdown at /peptides/bpc-157.

TB-500 (thymosin beta-4): a real repair signal from biology

TB-500 is the name usually attached to a synthetic version of thymosin beta-4, a small protein your own cells already make. Its day job is binding actin, one of the building blocks cells use to move and reshape themselves, which places it in the middle of tissue-repair biology. In rodent wound models, thymosin beta-4 has been associated with faster re-epithelialisation than saline controls, alongside more collagen and new blood-vessel growth. Review articles describe it as a genuine actin-sequestering, repair-linked molecule, but again the persuasive data sits in cell and animal systems rather than in human trials of the injectable 'TB-500' sold online. If you want the specifics on where TB-500 and thymosin beta-4 part ways, our TB-500 data sheet at /peptides/tb-500 lays it out.

GHK-Cu: the copper peptide with the most human data

GHK-Cu is the one that partly breaks the animal-only pattern. It is a naturally occurring copper-binding tripeptide, first isolated from human plasma in the 1970s, whose level in the body falls with age. Because it turns up in skincare, it has actually been studied in people: reviews credit topical GHK-Cu with a role in collagen production, wound healing and skin regeneration, and describe it as a broad modulator of repair-related pathways. It still is not a magic fix for injuries, and most of the human work is cosmetic rather than orthopaedic, but of the compounds on the biohacker shortlist it has the strongest human footprint. Our GHK-Cu page at /peptides/ghk-cu covers the topical-versus-injectable nuance in detail.

NAD: the popular one that is not even a peptide

NAD is not a peptide, but it appears constantly alongside these compounds, so an honest index has to include it. NAD is a coenzyme central to cellular energy and DNA-repair machinery, and its levels are widely reported to decline with age — the observation that turned NAD and its precursors into a longevity headline. Here the human data is actually more developed than for most peptides, and also more sobering. A 2024 meta-analysis of randomised controlled trials found that supplementing the precursor NMN produced no significant benefit for glucose control or lipid profile in adults. People report more energy; the controlled data is far more restrained. Our NAD page at /peptides/nad lays out what has and has not been shown.

MOTS-c: an intriguing mitochondrial peptide, almost all preclinical

MOTS-c is a mitochondrial-derived peptide, meaning it is encoded in mitochondrial rather than nuclear DNA — an unusual origin that made it genuinely interesting to metabolism researchers. In a 2015 study, MOTS-c was associated with better metabolic homeostasis and with reduced obesity and insulin resistance in mice, and its levels appear to shift with age and physical activity. That is a legitimately intriguing signal. It is also, at this point, almost entirely preclinical: robust human trials are lacking, and what MOTS-c does in people over time is unknown. It sits squarely in the promising-in-the-lab, unproven-in-humans bucket that defines most of this category. See our MOTS-c page at /peptides/mots-c for the detail.

What the evidence does not show

Here is the part the marketing skips. For almost every compound on the biohacker shortlist, the strongest data lives in cells and animals, not in long controlled human trials — and animal results have a long history of failing to carry over to people. No peptide here has been shown to slow human aging, speed human injury recovery or extend a human life. 'Studied for a repair pathway' or 'linked to a longevity marker' is a much smaller claim than 'works in people,' and the gap between those two sentences is where most of the marketing lives. Reported experiences from users are anecdotes, not evidence, and there is no way to know how representative any single story is.

Benefits, cons and side effects: the honest picture

Front-loading the benefits is easy; the honest cons are what most sellers leave out. Because BPC-157, TB-500 and MOTS-c have barely been studied in people, their real side-effect profiles in humans are essentially uncharacterised, and reviewers specifically note that completed human studies are scarce and that these compounds already circulate on the gray market. 'Few reports' of harm is a sign of missing data, not of safety. Sitting on top of that is a supply problem: research-grade peptides are unregulated, and gray-market products have repeatedly been reported as under-concentrated, mislabelled or contaminated, so what is in the vial may not match the label. NAD precursors and topical GHK-Cu have longer human track records, but a track record in one setting does not transfer to an injectable product aimed at something else. The sober summary: interesting biology, thin human safety data, and a genuine risk from the unregulated supply chain.

The regulatory status, in plain terms

Here is the regulatory reality in one line: none of these is a medicine a doctor can prescribe. BPC-157, TB-500, GHK-Cu, NAD precursors and MOTS-c are not FDA-approved for treating any condition, and the research-grade versions are sold strictly for laboratory research use, not for human consumption. That research-use label is not a formality — it means no regulator has checked their quality, purity or safety for people, and for most of them the burden of proof has simply not been met. Anyone presenting these compounds as ready-made human solutions is getting well ahead of the evidence.

The bottom line on biohacker peptides

So, what peptides do biohackers actually use — and does any of it hold up? The names that dominate the conversation are BPC-157, TB-500, GHK-Cu, NAD and MOTS-c, and once the hype is stripped away they separate cleanly by evidence type rather than by marketing. BPC-157 and TB-500 are the most compelling laboratory stories and the least proven in humans; GHK-Cu has the deepest human data, but mostly for skin; NAD has real human trials that are largely underwhelming; and MOTS-c remains an intriguing preclinical signal. Treat every claim as a hypothesis from cell or animal work until a real human trial says otherwise, weigh the unregulated-supply risk, and read the individual research write-ups linked above before trusting anyone selling a protocol. And because this is a question about your own body, a qualified clinician is a better source than a storefront.